Cytosorbents (NASDAQ:CTSO) Earns “Buy” Rating from D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the medical research company’s stock.

Several other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a report on Tuesday, October 14th. HC Wainwright dropped their target price on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $0.64 on Tuesday. The business’s 50 day moving average price is $0.76 and its 200-day moving average price is $0.93. Cytosorbents has a fifty-two week low of $0.60 and a fifty-two week high of $1.61. The company has a market cap of $40.38 million, a P/E ratio of -3.57 and a beta of 1.28. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Friday, January 3rd. The medical research company reported ($0.08) EPS for the quarter. Cytosorbents had a negative return on equity of 101.14% and a negative net margin of 27.77%.The firm had revenue of $8.61 million for the quarter. Sell-side analysts predict that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares during the period. Avenir Corp increased its holdings in Cytosorbents by 63.1% during the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock worth $5,045,000 after purchasing an additional 1,950,972 shares during the period. Vanguard Group Inc. raised its position in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Cytosorbents in the 3rd quarter worth $161,000. Finally, Citadel Advisors LLC grew its position in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after buying an additional 36,790 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.